XILIO
Dead / Abandoned — Abandoned — after publication (as of 06 Dec 2022)
What this means for you
This application is over — abandoned 05 Dec 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88783246
- Mark type
- Stylized text
- Filed
- 03 Feb 2020
- Published for opposition
- 02 Jun 2020
- Abandoned
- 05 Dec 2022
- Attorney of record
- Valerie Brennan
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the treatment of cancer, all of the foregoing excluding pharmaceutical products for sleep disorders, central nervous disorders (other than cancers of the central nervous system), and neurological disorders (other than cancers of the neurological system)
Owner
- XILIO DEVELOPMENT, INC., Waltham, MA, US
- Akrevia Therapeutics, Inc., Cambridge, MA, US
- Akrevia Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 06 Dec 2022 — ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
- 06 Dec 2022 — ABANDONMENT - AFTER PUBLICATION
- 05 Dec 2022 — TEAS EXPRESS ABANDONMENT RECEIVED
- 20 May 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 May 2022 — SOU EXTENSION 3 GRANTED
- 11 May 2022 — SOU EXTENSION 3 FILED
- 11 May 2022 — SOU TEAS EXTENSION RECEIVED
- 25 Nov 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Nov 2021 — SOU EXTENSION 2 GRANTED
- 23 Nov 2021 — SOU EXTENSION 2 FILED
- 23 Nov 2021 — SOU TEAS EXTENSION RECEIVED
- 09 Jun 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jun 2021 — SOU EXTENSION 1 GRANTED
- 07 Jun 2021 — SOU EXTENSION 1 FILED
- 07 Jun 2021 — SOU TEAS EXTENSION RECEIVED